3061B |
Milnacipran/Levomilnacipran, Blood |
3061SP |
Milnacipran/Levomilnacipran, Serum/Plasma |
3061U |
Milnacipran/Levomilnacipran, Urine |
3063B |
Mycophenolic Acid and Metabolite, Blood |
3063SP |
Mycophenolic Acid and Metabolite, Serum/Plasma |
3063U |
Mycophenolic Acid and Metabolite, Urine |
3064B |
Mitragynine, Blood |
3064SP |
Mitragynine, Serum/Plasma |
3075B |
Mirtazapine, Blood |
3075SP |
Mirtazapine, Serum/Plasma |
3075U |
Mirtazapine, Urine |
3078U |
Mitragynine (Qualitative), Urine |
3145B |
Nefazodone, Blood |
3145SP |
Nefazodone, Serum/Plasma |
3145U |
Nefazodone, Urine |
3168B |
Nitazenes Panel, Blood |
3218B |
N,N-Dimethylpentylone & Pentylone, Blood |
3218SP |
N,N-Dimethylpentylone & Pentylone, Serum/Plasma |
3218U |
N,N-Dimethylpentylone & Pentylone, Urine |
3220B |
Nortriptyline, Blood |
3220SP |
Nortriptyline, Serum/Plasma |
3220TI |
Nortriptyline, Tissue |
3220U |
Nortriptyline, Urine |
3224B |
NPS Stimulants (Qualitative), Blood |
3224SP |
NPS Stimulants (Qualitative), Serum/Plasma |
3224U |
NPS Stimulants (Qualitative), Urine |
3360B |
Paroxetine, Blood |
3360FL |
Paroxetine, Fluid |
3360SP |
Paroxetine, Serum/Plasma |
3360TI |
Paroxetine, Tissue |
3360U |
Paroxetine, Urine |
3426B |
Perfluorooctanoic Acid, Blood Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3427SP |
Perfluoroalkyl Substances (PFAS), Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3428SP |
PFASure TM, Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3429SP |
PFASure TM Expanded, Serum/Plasma Overview: Monitoring for exposure to Per- and Polyfluorinated alkyl substances |
3550B |
Phenelzine, Blood |
3550SP |
Phenelzine, Serum/Plasma |
3550U |
Phenelzine, Urine |